CD8A and glioblastoma: In these studies, we explored in vivo and ex vivo CD8 ImmunoPET imaging for the noninvasive monitoring of CD8+ cells under single agent and combination M002 oHSV and anti-PD1 immunotherapy in preclinical GBM models.